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Aims Pulmonary arterial hypertension (PAH) occurs more frequently in women with mutations in bone morphogenetic
protein receptor type 2 (BMPR2) and dysfunctional BMPR2 signalling underpinning heritable PAH. We have previously
shown that serotonin can uncover a pulmonary hypertensive phenotype in BMPR2+/2 mice and that oestrogen can in-
crease serotinergic signalling in human pulmonary arterial smooth muscle cells (hPASMCs). Hence, here we wished to
characterize the expression of oestrogen receptors (ERs) in male and female human pulmonary arteries and have exam-
ined the influence of oestrogen and serotonin on BMPR2 and ERa expression.
Methods
and results
By immunohistochemistry, we showed that ERa, ERb, and G-protein-coupled receptors are expressed in human pul-
monary arteries localizing mainly to the smooth muscle layer which also expresses the serotonin transporter (SERT).
Protein expression of ERa protein was higher in female PAH patient hPASMCs compared with male and serotonin
also increased the expression of ERa. 17b-estradiol induced proliferation of hPASMCs via ERa activation and this
engaged mitogen-activated protein kinase and Akt signalling. Female mice over-expressing SERT (SERT+ mice)
develop PH and the ERa antagonist MPP attenuated the development of PH in normoxic and hypoxic female SERT+
mice. The therapeutic effects of MPP were accompanied by increased expression of BMPR2 in mouse lung.
Conclusion ERa is highly expressed in female hPASMCs from PAH patients and mediates oestrogen-induced proliferation of
hPASMCs via mitogen-activated protein kinase and Akt signalling. Serotonin can increase ERa expression in
hPASMCs and antagonism of ERa reverses serotonin-dependent PH in the mouse and increases BMPR2 expression.
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1. Introduction
The incidence of pulmonary arterial hypertension (PAH) is greater in
females. For example, the female-to-male ratio is currently reported
in the REVEAL Registry as approximately 4.1:1 for idiopathic PAH
(IPAH) and 3.8:1 for associated PAH (APAH).1,2 Dysfunctional bone
morphogenetic protein receptor 2 (BMPR2) signalling is recognized to
play a pivotal role in the development of PAH and mutations in
BMPR2 are responsible for 80% of heritable PAH (HPAH) cases.3
Female gender is also known to increase the penetrance of BMPR2
mutations in HPAH.3 Reasons for these gender differences remain
unclear, however, there is converging evidence suggesting that sex
hormones, in particular oestrogens, are a major risk factor in females
with PAH and play a pivotal role in PAH pathogenesis. Clinically, poly-
morphisms in aromatase (CYP19A1), the enzyme that synthesizes oes-
trogen, are associatedwith higher oestrogen levels and an increased risk
of PH development in female patients with advanced liver disease.4 In
line with this, physiological concentrations of oestrogen mediate prolif-
eration of human PASMCs and an inhibitor of endogenous oestrogen
synthesis can reverse the development of PH in female rodents.5,6
We have previously demonstrated that serotonin can uncover a
PHphenotype in BMPR2+/2mice via decreasedBMPR2 signalling.7Mul-
tiple studies have implicated serotonin and the serotonin transporter
(SERT) in the pathogenesis of PAH. SERToverexpression and/or activity
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are observed in pulmonary arteries and lungs from patients with
PAH and are associated with an exaggerated proliferative response.8
In serotonin-dependent rodent models of pulmonary hypertension
(PH), including mice over-expressing the calcium-binding protein
S100A4 (Mts1), dexfenfluramine-treated mice and mice over-
expressing the SERT+, only the female mice develop PH.9– 11 We
have also previously demonstrated that 17b-estradiol plays a key
role in the development of PAH in female SERT+ mice.6 For
example, ovariectomized female SERT+ mice do not develop PAH,
while re-introduction of 17b-estradiol completely re-establishes the
disease phenotype.6 At the cellular level, 17b-estradiol can up-regulate
SERT expression and proliferation in human pulmonary arterial smooth
muscle cells (hPASMCs).6
The effects of oestrogen are primarily mediated by the activation of
three oestrogen receptors (ERs), ERa, ERb, and G-protein-coupled re-
ceptor (GPER).12 ERa andERbmediate both genomic andnon-genomic
oestrogen signalling, while very rapid non-genomic effects of oestrogen
have been attributed to theGPER. Experimentally administered exogen-
ous oestrogen can protect against hypoxic PH in intactmale rats and this
is mediated by ERa and ERb.13 However, we have recently demon-
strated that hPASMCs synthesize oestrogen endogenously via aroma-
tase expression and this expression is increased in female hPASMCs.5
This endogenous oestrogen plays a pathogenic role in the development
of PH in female rats and mice and this may be via decreased BMPR2
expression. Indeed, inhibition of ERa reverses PH in female hypoxic
mice while having no effect in male hypoxic mice.5
The aims of this study were therefore to characterize the expression
of ERs in human lung and PASMCs and to examine the role of endogen-
ous oestrogen, via ERa activation, in a serotonin and oestrogen-
dependent mouse model, the female SERT+mouse.
2. Methods
2.1 Ethical information
All experimental procedures conform with the United Kingdom Animal
Procedures Act (1986) and with the ‘Guide for the Care and Use of La-
boratory Animals’ published by the US National Institutes of Health
(NIH publication No. 85-23, revised 2011), and ethical approval was also
granted by the University of Glasgow Ethics Committee. Experimental
procedures utilizing human pulmonary artery smooth muscle cells
(PASMCs) conformed with the principles outlined in the Declaration of
Helsinki. Informed consent was given for the use of cells. Studies were
approved by Cambridgeshire 1 Research Ethics committee (REC refer-
ence: 08/H0304/56).
2.2 Generation of genetically modified
SERT1 mice
Mice over-expressing the human SERT gene transcript were generated and
supplied by Professor Tony Harmer, University of Edinburgh, UK. SERT+
micewere generated using theC57BL/6×CBAwild-type strain. See Supple-
mentary material online for more details.
2.3 In vivo effects of MPP dihydrochloride
administration
Two days prior to the induction of chronic hypoxia, SERT+ mice and/or
control littermates were administered with slow release pellets contain-
ing either ERa antagonist, MPP dihydrochloride [chemical name- 1,3-Bis
(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyra-
zole dihydrochloride] (MPP) 2 mg kg21 day21, or vehicle. See Supplemen-
tary material online for more details.
2.4 Assessment of PH in vivo and vascular
remodelling assessment
All haemodynamicmeasurementswere carried out under general anaesthe-
sia using 1–2% (v/v) isoflurane supplementedwithO2. Right-ventricular sys-
tolic pressure (RVSP) was measured by a transdiaphragmatic approach by
advancing a heparinized needle into the mid-portion of the abdomen using
a micromanipulator.14
Systemic arterial pressure (SAP) was obtained by cannulation of the left
common carotid artery as previously described.14 Right-ventricular hyper-
trophy (RVH) was assessed as a ratio of the weight of the right ventricle
(RV) over the weight of the free left ventricle plus septum (LV+S). Haemo-
dynamic assessment was carried out in 6–12 mice for each group. Animals
were randomly allocated to groups and all measurements, assessments,
and analysis carried out in a blinded fashion. See Supplementary material
online for more details
2.5 Vascular remodelling assessment
Pulmonary vascular remodelling was assessed in lung sections stained with
alpha-smooth muscle actin and microscopically examined. See Supplemen-
tary material online for more details.
2.6 Oestrogen receptor and SERT
immunolocalization in human lung
Briefly, 5 mm sagittal sections of fixed human lung were deparifinized and
rehydrated as discussed earlier. After epitope retrieval, oestrogen receptor
(ER) alpha (ERa) (Santa Cruz, sc-7207; 1 mg/mL), ERb (Abcam, ab-3577;
5 mg/mL), GPER (Abcam, ab-39742; 5 mg/mL), and SERT (Abcam,
ab-44520: 1:200) were incubated overnight at 48C. Lung sections were
counterstained with haematoxylin. Distribution was assessed by staining
consecutive sections with alpha smooth muscle actin (for medial cells) and
von-Williebrand factor (for endothelial cells).
2.7 Human PASMC proliferation
Proliferation in hPASMCswas assessed bymeasuringDNAsynthesis by [3H]
thymidine incorporation15 in the presence of agonists for ERa, ERb, and
GPER [4,4′,4′′-(4-Propyl-[1H ]-pyrazole-1,3,5-triyl)trisphenol (PPT), Diaryl-
propionitrile or 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN) & (+)-1-
[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3
H-cyclopenta[c]quinolin-8 -yl]-ethanone (G1), respectively] (0.01–
10 nmol/L) and 1 mM antagonists [ERa: MPP, ERb: 4-[2-Phenyl-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP), or
GPER: (3aS*,4R*,9bR*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-
cyclopenta [c]quinolone (G15)] where appropriate. See Supplementary
material online for more details.
2.8 Immunoblotting
Protein expression was assessed by western blotting in human PASMC
lysates and mouse pulmonary artery prepared as previously described9
and in more detail in the Supplementary material online.
2.9 Quantitative reverse transcription–
polymerase chain reaction (qRT-PCR)
Total RNA from mouse tissues and human cells were obtained using the
QIAGENRNeasymini-kit (Qiagen,Manchester, UK) following themanufac-
turer’s instructions.
Treatment with DNAse 1 (Qiagen) eliminated genomic DNA contamin-
ation prior to quantification using a NanoDrop ND-1000 Spectrophotom-
eter (Nano-Drop Technologies, Wilmington, DE, USA). High-capacity
cDNA Reverse Transcription kits (Life technologies, Paisley, UK) were
used for synthesis of cDNA from total RNA.
A mastermix containing dNTPs, random hexamers, and RNase inhibitor,
supplied in the kit was added to total RNA and the following cycling
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conditions were used to synthesize cDNA: 10 min at 258C, 30 min at 488C,
5 min at 958Cand128C forever.Quantitative real-timePCR (qRT-PCR)was
used tovalidatemRNAexpressionusingTaqManwGeneExpressionprobes
(Life Technologies, Paisley,UK), as previously described. See Supplementary
material online, Table S3 for details of assay IDs.
2.10 Statistics
Statistical analysis was performed using GraphPad Prism 6 Software. Data
were analysed using a two-way ANOVA followed by a Bonferroni’s
post-hoc test, one-way ANOVA followed by a Tukey’s or Dunnet’s post-hoc
test, or an unpaired t-test where appropriate. Data are expressed as+SEM.
3. Results
3.1 Expression of oestrogen receptors
and SERT in human lung and PASMCs
ER localization was investigated in human lung by immunohistochemis-
try. ERa, ERb, and GPER expressions were prominent in pulmonary
arteries in both control and PAH patients (Figure 1). In PAH patients,
ERa was localized to adventitia, smooth muscle cells, and endothelial
cells. While some ERb expression was observed in the adventitia and
smooth muscle cells, expression was largely endothelial. GPER was
also localized to vascular smoothmuscle. The SERT is clearly expressed
in the medial layer from patients with PAH. Localization was confirmed
by stainingof consecutive sectionswitha-smoothmuscle actin (a-SMA)
and Von Willebrand for smooth muscle and endothelial cells,
respectively (Figure 1).
ER expression was further investigated in male and female hPASMCs.
Levels of ERa and ERb proteinwere not significantly different in control
female and male hPASMCs (Figure 2A–D). However, in hPASMCs from
PAHpatients, ERa proteinwas expressed at significantly higher levels in
female hPASMCs relative tomales (Figure 2A and E) and female controls.
Conversely, ERb expression was significantly less in female hPASMCs
compared with males in PAH (Figure 2B and F ). ERb expression was
also significantly higher in male PAH cells compared with male control
cells.
3.2 Estrogen receptor-a and -b expression
in female SERT1 mouse lung
ER expression was also investigated in the pulmonary vasculature and
lungs from female SERT+ mice that develop spontaneous PH in nor-
moxic conditions. In pulmonary arteries from female SERT+ mice,
there was reduced ERa and ERb protein levels relative to wild-type
control mice (Figure 3A and B); the mRNA levels of ESR1 and ESR2,
the genes encoding ERa and ERb, were, however, found to be
unchanged in preparations from whole lung (Figure 3C and D).
Figure 1 Estrogen receptor and SERT expression profile in human lung. Localization was confirmed by staining of consecutive sections with a-smooth
muscle actin (a-SMA) andVonWillebrand (vWB) for smoothmuscle and endothelial cells, respectively. ERawasmainly localized to smoothmuscle in the
pulmonary arteries from control and PAH patients. ERb expression was largely endothelial (indicated with arrow). GPER staining was punctate in nature
and localized to a fewendothelial and smoothmuscle cells (indicatedwith arrow). SERTexpression is localized to the smoothmuscle in patient pulmonary
arteries. IgG, immunoglobulin control. Scale bar (2)¼200 mm. See Supplementary material online, Table S1 for patient details.
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3.3 Effect of ERa antagonism in the SERT1
female susceptible in vivo mouse model
We wished to investigate if ERa influenced the development of PH in a
model that we know to demonstrate female susceptibility. We have pre-
viously shown that normoxic female SERT+ mice develop spontaneous
PAH at 5 months of age in an estrogen-dependent manner, while male
SERT+mice do not.11,16 In the SERT+mice, the increase in RVSP and pul-
monary vascular remodelling was abolished by MPP (Figure 4A–C). We
also exposed these animals to hypoxia, where hypoxic wild-type mice
developed PH demonstrating increased RVSP and this was reduced by
MPP (Figure 4A–C). In vehicle-treated SERT+ mice, hypoxia caused
enhanced pulmonary vascular remodelling relative to hypoxic wild-type
vehicle-treated mice and this was also markedly reduced by MPP
(Figure 4B and C). The augmented elevations in RVSP were reversed by
MPP administration (Figure 4A) while RVH was unaffected (Figure 4D).
Meansystemicarterialpressure (mSAP)wasunaffectedbyMPPtreatment
(see Supplementary material online, Figure S1A).
3.4 Effects of ERaantagonism on the BMPR2
pathway in female SERT1 mice
To determine amechanism bywhich the estrogen/ERa interaction pro-
motes the pathogenesis of PH in female SERT+ mice, we investigated
BMPR2 expression in the animals treated with MPP. We examined
protein levels of BMPR2 in normoxic female SERT+ mice. Although
BMPR2 protein levels were unchanged between wild-type control
mice and SERT+ mice (Figure 5A), mRNA transcript was significantly
reduced in vehicle-treated SERT+ females compared with wild-type
controls (Figure 5B). Treatment with the ERa antagonist MPP resulted
in elevated protein levels of BMPR2 in wild-type mice (Figure 5A) and
both BMPR2 protein and mRNA transcript levels were increased by
MPP in SERT+ mice (Figure 5A and B).
3.5 Effects of ER agonists and antagonists
in human PASMCs in vitro
Our results demonstrated that ERa plays a role in the development of
PH in the female SERT + mouse model. In addition, we demonstrate
there are elevated expression levels of ERa in PASMCs from female
PAH patients. From these results, we hypothesized that activation of
ERa by endogenous oestrogen may be promoting PH especially in
females. To determine potential mechanisms by which ERa activation
could be facilitating changes in the pulmonary artery in PAH, we exam-
ined the effects of oestrogen in female human PASMCs.
Themajorcirculatingoestrogen17b-estradiolwasexaminedatphysio-
logical concentrations (0.1–1 nmol/L) and at a supraphysiological con-
centration of 10 nmol/L. At 1 nmol/L oestrogen-induced proliferation
(Figure 6A). The ERa selective agonist, PPT, also caused proliferation of
PASMCs at 0.01–0.1 nmol/L (Figure 6B), whereas diarylpropionitrile
(DPN), the ERb selective agonist and G1, the GPER selective agonist
Figure 2 Estrogen-receptor expression is altered betweenmale and female pulmonary artery smooth muscle cells (PASMCs) from PAH patients. ERa
and ERb protein expression in male (n ¼ 5) and female (n ¼ 6) PASMCs (A and B). Representative blots are shown (C–F ). Patient information detailed in
Supplementarymaterial online,Table S2. Control PASMCs: female 1–6,male 1–5; PAHPASMCs: female 1–3,male 1–3, repeated in triplicate.Quantitative
data are shown as mean+ SEM and analysed using two-way ANOVA followed by Bonferroni’s post -test. *P, 0.05, ***P, 0.001.
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had no proliferative effect (Figure 6C and D). 17b-estradiol-induced
proliferation at 1 nmol/L was inhibited by the ERa selective antagonist
MPP (1 mmol/L) while the ERb selective antagonist (PHTPP, 1 mmol/L)
and the GPER selective antagonist (G15,1 mmol/L) had no effect
(Figure 6E). Akt and MAPKs can phosphorylate and activate ERs and
their co-regulators to enhance nuclear transcription and regulate cell
survival and proliferation.17 We therefore examined the proliferative
effects of 17b-estradiol and PPT on PASMC proliferation in the presence
of LY294002, a PI3K inhibitor, and U0126, a MAPK/ERK kinase (MEK) in-
hibitor. Proliferative responses to 17b-estradiol were inhibited in the
presenceofU0126andLY294002(Figure6F).Wehavealsodemonstrated
thatphosphorylationofMAPK/ERKandAKT-1 is increased inresponseto
1 nmol/L 17b-estradiol (Figure 7A and B).
3.6 Effect of serotonin on ER expression
in human PASMCs
We have previously demonstrated that oestrogen can increase the ex-
pression of tryptophan hydroxylase 1 (TPH1; the rate limiting enzyme
in peripheral serotonin synthesis), SERT, and the 5-HT1B receptor.6
Here we wished to examine the effects of serotonin on ER expression
in human PASMCs.
In female PASMCs, we demonstrated that expression of ERa protein
was significantly increased (see Supplementary material online, Figure
S2A) while expression of ERb was significantly decreased by 1 mmol/L
serotonin applied for 24 h (see Supplementarymaterial online, Figure S2B).
4. Discussion
This study aimed to investigate the interaction of the ER, gender, and
serotonin in the development of PH. First, we investigated the classical
ERs, ERa, and ERb, which predominantly act as transcription factors
regulating gene expression, and the novel G-protein-coupled receptor,
GPER, which mediates rapid, non-genomic effects of oestrogen.12 ERa
expression was mainly localized to smooth muscle in the pulmonary
arteries from control and PAH patients. Likewise, SERT expression is
localized to the smooth muscle in patient pulmonary arteries. ERb
expression was largely endothelial. GPER expression was observed in
some endothelial and smooth muscle cells. In humans, expression of
ERa and ERb has previously been identified in endothelial cells and vas-
cular smoothmuscle cells of aortic and coronary vasculature aswell as in
cardiomyocytes.18,19 Thus the presence of both ERa and ERb mediate
physiologically important effects of oestrogen in the human vasculature.
Figure3 Estrogen-receptorexpression is reduced in female SERT+mousepulmonaryartery. ERa andERbprotein expression inpulmonaryartery from
female SERT+mice relative to controls (A and B). ESR1 mRNA transcript in whole lung (C and D). Representative blots are shown for ERa (n ¼ 12 pul-
monary arteries from12 animals) andERb (n ¼ 9pulmonary arteries fromnine animals) (A andB). Allwesterns repeated in triplicate; qRT–PCR, n ¼ 9–12
lungs/group. Quantitative data are shown as+SEM and analysed using an unpaired t-test. *P, 0.05, *P, 0.01 vs. wild-type (WT).
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Characterization of GPER is less well defined, although enhanced
GPER expression has recently been attributed to a pathological role in
lung cancer cells.20
We hypothesized that ERa drives the PAH phenotype in females.
Other studies have also suggested ERa activation plays a role in PAH.
For instance, gene expression data from one patient cohort demon-
strated an up-regulation of ESR1 in human PAH subjects relative to
controls.21 Polymorphisms in ESR1 have also been associated with an
increased risk of developing portopulmonary hypertension independ-
ent of gender.4 Uniquely, we report here that ERa expression is
markedly increased in human PASMCs from female PAH patients com-
paredwithmale, while ERb expression is greatest in PASMCs frommale
PAH patients. On the other hand, levels of ERa are unchanged between
male and female control hPASMCs. We therefore suggest the onset of
PAHhas a regulatoryeffectonERa in pulmonaryarteries. In addition, it is
known that ERb inhibits ERa-mediated gene transcription in the pres-
ence of ERa in mice and it is possible that such a relationship may influ-
ence ER signalling in the pulmonary vasculature.22 Curiously, ERb
expressionwas higher in human PASMCs frommale PAHpatients com-
pared with male controls. As we show that, in situ, ERb expression may
Figure4 MPP2 mg kg21 day21 attenuates thedevelopmentofpulmonaryhypertension in femaleSERT+mice. EffectofMPPonright-ventricular systolic
pressure (RVSP) in SERT+, hypoxic control, andhypoxic SERT+mice (A). EffectofMPPonpulmonary vascular remodelling innormoxic andhypoxic SERT+
mouse lungs (B and C). Effect of MPP on right-ventricular hypertrophy (RV/LV+S) in hypoxic mice (D). Representative images from distal pulmonary ar-
teries in each group are shown (alpha-smooth muscle actin stains dark brown, C). Data are expressed as+ SEM and analysed using two-way ANOVA
followed by a Bonferroni post-hoc t-test. *P, 0.05, **P, 0.01, ***P, 0.001 vs. normoxic mice. †P, 0.05, ††P, 0.01, †††P, 0.001 vs. vehicle dosed
mice. #P, 0.05, ##P, 0.01, ###P, 0.001 vs. wild-type mice. n ¼ 6–11 per group. WT, wild-type. Scale bar (2) ¼ 20 mm.
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be mainly endothelial, it is unclear if this would have pathophysiological
significance.
One limitation of our expression studies in this investigation is the
small number of isolated human PASMCs available due to the rare
nature of PAH. However, gender differences in tissue localization of
ERs during development and disease has been reported in other condi-
tions. In aortic vasculature during aneurysm, a correlation between
increased ERa expression in females but not males has been identified
and gender differences in vascular function has been attributed to differ-
ences in expression, distribution and/or activity of ERs in response to
vasoconstrictors.23–25 In the lungs of female mice, both ERa and ERb
are required for the full functional and morphological development of
alveoli structures, although they have a much smaller effect on alveolar
dimensions in male mice.26,27 It is likely then, that ERs contribute more
significantly to the pathophysiology of PAH in female lung compared
with male.
As we are interested in the interactions between serotonin and oes-
trogen, we investigated if inhibition of ERawith MPP would reverse PH
in our female SERT+ mouse model. We were also interested in deter-
mining if MPP could reverse the additional effects of hypoxia in the
SERT+ mouse. Our results demonstrate that the ERa antagonist MPP
did reverse PH in both the normoxic and hypoxic SERT+ mouse. This
suggests that activation of ERa by endogenous oestrogen plays a role
in the development of PH in SERT+ female mice. Curiously, ERa
protein expression was actually decreased in the lungs from the
SERT+ mice. However, we also show that serotonin is a stimulus for
ERa expression in hPASMCs. This suggests that the reduction in ERa
expression may be due to the reduction in extracellular serotonin con-
centrations due to the increased SERT activity. However, clearly there is
sufficient ERa expression remaining to mediate PH in the SERT+mice.
Hypoxia response elements have been identified on the promoters of
both ERa and ERb28 and in breast cancer cells, it has been demonstrated
that hypoxia induces ESR1 repression at the transcriptional level in a
process dependent on hypoxia-inducible factor 1a.29 This is consistent
with our observation that the ERa antagonist also reversed the
increased PH phenotype observed in the hypoxic SERT+ mice.
ERb protein expressionwas also reduced in the pulmonary arteries of
female normoxic SERT+ mice. Down-regulation of ERb has previously
been observed in the lung and right heart in a right heart failure rat
model.30 It has previously been shown that loss of ERb in female mice
leads to abnormal lung structures and systemic hypoxia contributing to
ventricular hypertrophy.31 ERb is likely therefore to be protective in
experimental PH as previously described in male rodent models.32,33
The reduced expression of ERb we observe in female human PASMCs
from PAH patients and in the female SERT+ model of PH may result in
a loss of the protective effects of oestrogen.
Male mice have lower circulating levels of oestrogen,5 and as shown
here, lowERaexpression. Itwouldnotbe surprising therefore, if oestro-
gen plays a lesser role in the development of PH inmales. This is consist-
ent with our observation that MPP only prevented the development of
hypoxia-induced PH in female mice and not male mice and inhibition of
oestrogen synthesis is protective only in female rodent (sugen/hypoxic
and hypoxic) models of PH.5 As we have demonstrated before, there
was no RVH in our normoxic SERT+ mice.16 Indeed we have
Figure 5 Regulation of the BMPR2 pathway via ERa in female SERT+mouse lung. Effect of MPP on BMPR2 protein in WT and SERT+ female lung (A).
Effect of MPP on BMPR2 mRNA transcript (B) in SERT+ mouse lung. Quantitative data are expressed as+ SEM and analysed by a two-way ANOVA
followed by a Bonferroni post-hoc t-test. *P, 0.05, **P, 0.05 n ¼ 6 lungs/group performed in triplicate.
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demonstrated that normoxicmice are resistant to changes inRVH in the
face of moderate changes in pulmonary pressures.10 MPP also failed to
influence the hypoxia-inducedelevation inRVH in themice. There is evi-
dence thatwhile oestrogen is pathogenic to the pulmonary circulation, it
may beprotective in the right ventricle.Womenare frequently reported
to have an improved prognosis comparedwithmendespite their predis-
position to developing PAH.34,35 This has been attributed to an RV
cardioprotective effect of oestrogen. Indeed oestrogen levels correlate
withhigher right-ventricularejection fractionandsurvival in females.36,37
Protective effects of exogenous oestrogen in PH observed in other
Figure6 Estrogen inducesproliferationof female humanPASMCsthroughERa in a PI3K/Akt andERKMAPK-dependentmanner. Effect of 17b-estradiol
(A) andPPT, anERa agonist (B),DPN, an ERb agonist (C) andG1, aGPERagonist (D) on proliferationof PASMCs. Effect of the ERa antagonist,MPP (1 mM),
an ERb selective antagonist PHTPP (1 mM)andGPER selective antagonistG15 (1 mM)onE2-inducedproliferationof PASMCs (E). Effect ofU0126 (1 mM),
a MEK inhibitor and LY294002 (1 mM), a PI3 K/Akt inhibitoron E2 (1 nM) and PPT (0.01 nM) induced proliferation of PASMCs (F). Data are expressed as
mean+ SEM and analysed using a one-way ANOVA followed by a Tukey’s post-hoc test. †††P, 0.001 vs. 0.2% FBS; *P, 0.05, **P, 0.01 vs. 2.5% FBS;
#P, 0.05, ##P, 0.01, ###P, 0.001 vs. E2/PPT. n ¼ 4 per experiment and performed in triplicate in separate female cell lines (Control PASMCs 1, 2,
3, and 5) depicted in Supplementary material online, Table S2 (passages 3–5).
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studies may therefore arise from a direct structural effect on the right
ventricle and an influence on right-ventricular function as opposed to
an effect on vascular remodelling and pulmonary artery pressures. It is
possible that the protective influence of oestrogen on the right ventricle
may be mediated predominantly by ERb.38,39 We see no effect of MPP
on systemic arterial function following treatment with MPP and so the
haemodynamic effects of ERa inhibition are selective to the pulmonary
circulation. From this study, we suggest oestrogen, via ERa, is implicated
in creating a pro-proliferative environment in the pulmonary arteries
leading to excessive pulmonary vascular remodelling in vivo.
Excessive smoothmuscle cell proliferation is amain componentof the
pulmonary vascular remodelling and vascular lesions observed in PAH.
Estrogen is a pro-proliferative factor in pulmonary smooth muscle
cells6,15 and breast cancer cells.40
This suggests that oestrogen may mediate proliferation of hPASMCs
and may contribute to PAH pathology. We investigated this further by
examining ERa-mediatedproliferation in female hPASMCs.Wedemon-
strate for the first time that oestrogen can induce proliferation of
hPASMCs via ERa activation. In addition, we show an ERb agonist,
DPN, and a GPER agonist G1, have no effect on proliferation of
PASMCs suggesting that ERa is the receptor that mediates estrogen-
induced proliferation in hPASMCs. Moreover, we determine the
pro-proliferative effect of oestrogen is dependent on activation of
downstream PI3K/Akt and ERK/MAPK signalling. ERK and Akt signalling
pathways are closely involved in cardiac hypertrophy and pulmonary
vascular remodelling and oestrogen has been shown to regulate activa-
tion of Akt signalling in right heart failure.32,41 Additionally, selective
activation of ERa in endothelial cells in aorta increases ERK expression
and ERK1/2-mediated cell proliferation. Furthermore activationof PI3K/
Akt in human endothelial cells is dependent on ERa but not ERb.42,43
These results provide some insight into the molecular mechanisms by
which oestrogen and ERamaymediate pulmonary vascular remodelling
during PH and explain the reduction in pulmonary vascular remodelling
observed in females following MPP treatment in SERT+mice.
Loss of BMPR2 function mediates proliferation of PASMCs by redu-
cing induction of cell-cycle inhibitors, the Id proteins, particularly Id1
and Id3 in hPASMCs.44A gene–gender relationship for BMPR2was pro-
posed in a recent study where BMPR2 expression was shown to be
decreased in lymphocytes and whole lung from female patients com-
pared with males and BMPR2 was identified as a gene target of
ESR1.45 It has previously been shown that BMPR2 protein and mRNA
expression are decreased following hypoxia in PH.46,47 We show here
that BMPR2 mRNA expression is decreased in SERT+ mice and this is
rescued by MPP. BMPR2 protein expression was not decreased in
SERT+ lung. However, expression levels of BMPR2 protein have been
shown to be already relatively low in female mouse lung compared
with male. Indeed we show that MPP increased lung BMPR2 expression
in both wild-type and SERT+mouse lung. Hence the therapeutic effects
of MPP may be associated with increased BMPR2 expression which
would exert an anti-proliferative effect. This is consistent with the
ability of anastrozole (and hence decreased endogenous oestrogen)
to rescue decreased BMPR2 signalling in female mice5 and the proposal
that BMPR2 signalling is suppressed via ERa binding to the BMPR2
promoter.45
In conclusion, development of PH in female SERT+mice is dependent
on oestrogen and here we show this is mediated via the ERa receptor
Figure 7 Stimulation of female human PASMCswith 17b-estradiol increases AKT phosphorylation. Effect of 1 nM 17b-estradiol on phosphorylation of
ERK-1/2 (A) and AKT-1 (B) in PASMCs. Representative blots are shown. n ¼ 3, *P, 0.05 and ***P, 0.001 vs. 0 time-point control.
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which may rescue BMPR2 expression. We also show there is increased
ERa expression in hPASMCs from female PAH patients and that sero-
tonin can increase ERa expression in hPASMCs. 17b-estradiol can
induce proliferative signalling in hPASMCs. These conclusions suggest
causative and co-operative roles for oestrogen and serotonin in the
developmentof pulmonaryhypertension in females and are summarized
in Supplementary material online, Figure S3.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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